Slowing Progression in CKD: DAPA CKD and Beyond.
作者信息
Larmour Kathryn, Levin Adeera
机构信息
Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
出版信息
Clin J Am Soc Nephrol. 2021 Jul;16(7):1117-1119. doi: 10.2215/CJN.20211220. Epub 2021 Mar 10.
Abstract
摘要
相似文献
1
Slowing Progression in CKD: DAPA CKD and Beyond.
Clin J Am Soc Nephrol. 2021 Jul;16(7):1117-1119. doi: 10.2215/CJN.20211220. Epub 2021 Mar 10.
2
Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Nephrology (Carlton). 2021 Nov;26(11):858-871. doi: 10.1111/nep.13917. Epub 2021 Jul 6.
3
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
4
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Semin Nephrol. 2016 Nov;36(6):436-447. doi: 10.1016/j.semnephrol.2016.08.001.
5
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4.
6
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282. doi: 10.1093/ndt/gfz290.
7
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4.
8
DAPA-CKD: Significant Victory for CKD with or without Diabetes.
Trends Endocrinol Metab. 2021 Jun;32(6):335-337. doi: 10.1016/j.tem.2021.02.007. Epub 2021 Mar 4.
9
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.
Endocr J. 2020 Nov 28;67(11):1127-1138. doi: 10.1507/endocrj.EJ20-0222. Epub 2020 Jul 1.
10
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Curr Opin Nephrol Hypertens. 2021 Jan;30(1):123-130. doi: 10.1097/MNH.0000000000000659.
引用本文的文献
1
Trends in Co-morbid Dementia and Chronic Kidney Disease.
J Gen Intern Med. 2025 Jan 14. doi: 10.1007/s11606-024-09069-y.
2
Chronic Kidney Disease in Brazil: Current Status and Recommended Improvements.
Kidney Dis (Basel). 2024 Feb 29;10(3):213-223. doi: 10.1159/000538068. eCollection 2024 Jun.
3
Overcoming barriers to deliver high quality kidney care.
Nat Rev Nephrol. 2024 Mar;20(3):149-150. doi: 10.1038/s41581-024-00807-3.
4
CHA2DS2VASc score predicts risk of end stage renal disease in patients with atrial fibrillation: Long-term follow-up study.
Heliyon. 2023 Feb 22;9(3):e13978. doi: 10.1016/j.heliyon.2023.e13978. eCollection 2023 Mar.
5
Cardiac Valve Disease and Prevalent and Incident CKD in Community-Dwelling Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study.
Kidney Med. 2022 Oct 15;4(12):100559. doi: 10.1016/j.xkme.2022.100559. eCollection 2022 Dec.
6
Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease.
Clin Kidney J. 2022 Feb 21;15(8):1534-1541. doi: 10.1093/ckj/sfac048. eCollection 2022 Aug.
7
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression.
Clin Kidney J. 2022 Feb 16;15(7):1403-1414. doi: 10.1093/ckj/sfac044. eCollection 2022 Jul.
Zotero 插件